These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28636806)

  • 1. pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.
    Penketh PG; Finch RA; Sauro R; Baumann RP; Ratner ES; Shyam K
    Chem Biol Drug Des; 2018 Jan; 91(1):62-74. PubMed ID: 28636806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
    Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W.
    Penketh PG; Shyam K; Zhu R; Baumann RP; Ishiguro K; Sartorelli AC
    Chem Res Toxicol; 2014 May; 27(5):818-33. PubMed ID: 24618018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of glutathione and glutathione S-transferases on DNA interstrand cross-link formation by 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, the active anticancer moiety generated by laromustine.
    Penketh PG; Patridge E; Shyam K; Baumann RP; Zhu R; Ishiguro K; Sartorelli AC
    Chem Res Toxicol; 2014 Aug; 27(8):1440-9. PubMed ID: 25012050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
    Ishiguro K; Seow HA; Penketh PG; Shyam K; Sartorelli AC
    Mol Cancer Ther; 2006 Apr; 5(4):969-76. PubMed ID: 16648568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death.
    Ji W; Yang M; Praggastis A; Li Y; Zhou HJ; He Y; Ghazvinian R; Cincotta DJ; Rice KP; Min W
    PLoS One; 2014; 9(7):e103224. PubMed ID: 25068797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.
    Rice KP; Klinkerch EJ; Gerber SA; Schleicher TR; Kraus TJ; Buros CM
    Mol Cell Biochem; 2012 Nov; 370(1-2):199-207. PubMed ID: 22864532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.
    Baumann RP; Shyam K; Penketh PG; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):288-95. PubMed ID: 14685775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
    Ishiguro K; Shyam K; Penketh PG; Sartorelli AC
    Mol Cancer Ther; 2005 Nov; 4(11):1755-63. PubMed ID: 16275997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.
    Pigneux A
    IDrugs; 2009 Jan; 12(1):39-53. PubMed ID: 19127504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.
    Rice KP; Penketh PG; Shyam K; Sartorelli AC
    Biochem Pharmacol; 2005 May; 69(10):1463-72. PubMed ID: 15857610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
    Zhu R; Baumann RP; Patridge E; Penketh PG; Shyam K; Ishiguro K; Sartorelli AC
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1853-9. PubMed ID: 23395657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.
    Penketh PG; Shyam K; Baumann RP; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):279-87. PubMed ID: 14704831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of laromustine (Onrigin™) in hematologic malignancies.
    Alvarado Y; Swords R; Kelly KR; Giles FJ
    Expert Rev Hematol; 2009 Oct; 2(5):481-8. PubMed ID: 21083013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.
    Baumann RP; Penketh PG; Ishiguro K; Shyam K; Zhu YL; Sartorelli AC
    Biochem Pharmacol; 2010 Jun; 79(11):1553-61. PubMed ID: 20005211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
    Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
    Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.
    Penketh PG; Baumann RP; Ishiguro K; Shyam K; Seow HA; Sartorelli AC
    Leuk Res; 2008 Oct; 32(10):1546-53. PubMed ID: 18479747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).
    Nassar AE; King I; Du J
    Chem Res Toxicol; 2011 Apr; 24(4):568-78. PubMed ID: 21361357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
    Finch RA; Shyam K; Penketh PG; Sartorelli AC
    Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine.
    Frederick AM; Davis ML; Rice KP
    Biochem Biophys Res Commun; 2009 Jan; 378(3):419-23. PubMed ID: 19026985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.